Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE1/PHASE2

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Rationale: Giving bortezomib and low doses of chemotherapy and total-body irradiation before a donor stem cell transplant or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving sirolimus and tacrolimus before and after transplant may stop this from happening.

Purpose: This phase I/II trial is studying the side effects and best dose of bortezomib before donor stem cell transplant in treating patients with multiple myeloma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

NCT01936090

DS Stage I Plasma Cell Myeloma DS Stage II Plasma Cell Myeloma DS Stage III Plasma Cell Myeloma +1 more

COMPLETED PHASE1

Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients

NCT02308280

Multiple Myeloma High-Risk Cancer

COMPLETED PHASE2

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

NCT00793572

Refractory Plasma Cell Myeloma

COMPLETED PHASE2

Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

NCT01954784

Refractory Multiple Myeloma Stage I Multiple Myeloma Stage II Multiple Myeloma +1 more

TERMINATED PHASE1

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT01055301

Multiple Myeloma Plasma Cell Myeloma

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Objectives:

I. To determine the maximum tolerated dose (MTD) of bortezomib when used in a novel conditioning regimen for patients undergoing allogeneic stem cell transplantation for multiple myeloma.

II. To evaluate the tolerability and feasibility of this novel conditioning regimen and GVHD prophylaxis strategy incorporating several anti-myeloma agents, including bortezomib, in patients undergoing allogeneic stem cell transplantation for multiple myeloma.

III. To obtain an initial assessment of the efficacy of this novel conditioning regimen.

Outline: This is a phase I dose-escalation study of bortezomib followed by a phase II study.

Reduced-Intensity Conditioning: Patients receive bortezomib IV and then undergo fractionated total-body irradiation on days -5 and -2. Patients receive thymoglobulin IV over 6 hours on days -5 to -2 and melphalan IV over 30 minutes on days -4 to -3.

Allogenic Stem Cell Transplantation: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0.

Graft versus Host Disease Prophylaxis: Beginning on day -3, patients receive oral sirolimus and taper beginning on day 61. Beginning on day -2, patients receive oral or IV tacrolimus and taper beginning on day 101. After completion of the study treatment, patients are followed every 3 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Myeloma Refractory Multiple Myeloma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1

CONDITIONING: Patients receive bortezomib IV and then undergo fractionated total-body irradiation on days -5 and -2. Patients receive thymoglobulin IV over 6 hours on days -5 to -2 and melphalan IV over 30 minutes on days -4 to -3. ALLOGENEIC STEM CELL TRANSPLANTATION: Patients undergo bone marrow or peripheral blood stem cell transplant on day 0. GRAFT-VS-HOST DISEASE PROPHYLAXIS: Beginning on day -3, patients receive oral sirolimus and taper beginning on day 61. Beginning on day -2, patients receive oral or IV tacrolimus and taper beginning on day 101.

Group Type EXPERIMENTAL

nonmyeloablative allogeneic hematopoietic stem cell transplantation

Intervention Type PROCEDURE

Undergo transplantation

allogeneic bone marrow transplantation

Intervention Type PROCEDURE

Undergo transplantation

bortezomib

Intervention Type DRUG

Given IV

melphalan

Intervention Type DRUG

Given IV

anti-thymocyte globulin

Intervention Type DRUG

Given IV

sirolimus

Intervention Type DRUG

Given orally

tacrolimus

Intervention Type DRUG

Given oral or IV

total-body irradiation

Intervention Type RADIATION

Undergo total-body irradiation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

nonmyeloablative allogeneic hematopoietic stem cell transplantation

Undergo transplantation

Intervention Type PROCEDURE

allogeneic bone marrow transplantation

Undergo transplantation

Intervention Type PROCEDURE

bortezomib

Given IV

Intervention Type DRUG

melphalan

Given IV

Intervention Type DRUG

anti-thymocyte globulin

Given IV

Intervention Type DRUG

sirolimus

Given orally

Intervention Type DRUG

tacrolimus

Given oral or IV

Intervention Type DRUG

total-body irradiation

Undergo total-body irradiation

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

bone marrow therapy, allogeneic bone marrow therapy, allogenic transplantation, allogeneic bone marrow transplantation, allogenic bone marrow LDP 341 MLN341 PS-341 VELCADE Alkeran CB-3025 L-PAM L-phenylalanine mustard L-Sarcolysin Melfalan ATG ATGAM lymphocyte immune globulin Thymoglobulin AY 22989 RAPA Rapamune rapamycin SILA 9268A SLM Advagraf FK 506 Prograf Protopic TBI

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ECOG performance status (PS) 0, 1, or 2
* Diagnosis of symptomatic multiple myeloma
* High risk myeloma as defined by progressive disease =\< 12 months after high dose chemotherapy and autologous HSC transplant or presences of poor prognostic features such as deletion of chromosome 13 or hypodiploidy by standard cytogenetics, or t(4; 14) by fluorescence in situ hybridization (FISH), or t(14;16) by FISH, or 17p- by FISH, or plasma cell labeling index \>= 3%
* Availability of a HLA fully-matched or 1 mismatch related donor by low-resolution HLA typing for the loci A, B, C, DRB1 and DQB1 or HLA fully-matched unrelated donor by high-resolution typing for loci A, B, C and DRB1 and at least low-resolution for loci DQB1
* Recovery from toxicity of previous chemotherapy (excludes grade 1 neurotoxicity and hematological toxicity)
* Physically and psychologically capable of undergoing bone marrow or PBSC transplant
* Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care
* Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control for the during of the study
* Male subject agrees to use an acceptable method for contraception for the duration of the study

Exclusion Criteria

* Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV hear failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
* NOTE: Prior to study entry, and ECG abnormality at screening has to be documented by the investigator as not medically relevant
* Significant cardiac dysfunction defined as left ventricle ejection fraction \< 40% or presence of symptomatic coronary artery disease
* Significant pulmonary disease defined as FEV \< 50% or CLCO \< 50% of the predicted values
* Pre existing peripheral neuropathy grade \> 1
* Significant renal dysfunction defined as estimated creatinine clearance \< 50 ml/min
* Significant liver dysfunction defined as total bilirubin \>= 2 x upper limit of normal (ULN) or AST, ALT \>= 3 x ULN
* Seroreactive for HIV, HTLV I or II, HBV, HCV
* Presence of uncontrolled bacterial, viral, or fungal infection
* Known allergy to any of the component of the investigational treatment regimen or required ancillary treatments
* Considered unable to tolerate the included doses of total body irradiation due to previous treatment with radiation
* Female subject is pregnant or breast-feeding
* Other active concurrent malignancy
* Prior allogeneic bone marrow/peripheral blood stem cell transplant
* Received other investigational drugs =\< 14 days prior to enrollment

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No